HC Wainwright Analysts Lift Earnings Estimates for ProKidney

ProKidney Corp. (NASDAQ:PROK) – Equities research analysts at HC Wainwright upped their Q2 2026 earnings estimates for shares of ProKidney in a note issued to investors on Monday, May 18th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.11) per share for the quarter, up from their previous forecast of ($0.13). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for ProKidney’s Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.54) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at ($0.37) EPS.

Other analysts have also issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProKidney in a research note on Tuesday, April 21st. Wall Street Zen lowered shares of ProKidney from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, Jefferies Financial Group upgraded shares of ProKidney to a “strong-buy” rating in a research report on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.40.

ProKidney Price Performance

NASDAQ PROK opened at $1.55 on Wednesday. ProKidney has a 1 year low of $0.54 and a 1 year high of $7.13. The firm has a market cap of $467.98 million, a price-to-earnings ratio of -2.92 and a beta of 1.70. The company has a fifty day moving average price of $1.93 and a 200-day moving average price of $2.16.

ProKidney (NASDAQ:PROK) last posted its earnings results on Friday, May 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.10 million.

Hedge Funds Weigh In On ProKidney

Institutional investors have recently added to or reduced their stakes in the stock. R Squared Ltd bought a new position in ProKidney during the first quarter valued at about $25,000. SummitTX Capital L.P. bought a new position in ProKidney during the first quarter valued at about $26,000. Cetera Investment Advisers bought a new position in ProKidney during the fourth quarter valued at about $28,000. AQR Capital Management LLC grew its position in ProKidney by 106.4% during the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock valued at $46,000 after buying an additional 27,098 shares during the period. Finally, EntryPoint Capital LLC bought a new position in ProKidney during the fourth quarter valued at about $65,000. Institutional investors own 51.59% of the company’s stock.

More ProKidney News

Here are the key news stories impacting ProKidney this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on ProKidney and kept a $12.00 price target, implying significant upside from current levels. The firm also raised near-term earnings estimates for Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, and FY2028, which suggests improving expectations for the company’s loss profile.
• Neutral Sentiment: HC Wainwright’s estimate changes were mixed across the out years, with FY2030 lowered while earlier periods were revised higher. That makes the overall message positive on the nearer-term outlook but less uniformly bullish long term. FY2030 EPS Estimates for ProKidney Lowered by HC Wainwright
• Neutral Sentiment: Recent commentary from the analyst also appears to have repeated the same core view: a Buy rating with a high price target, but the company is still expected to remain unprofitable in the near term.
• Negative Sentiment: Even with the analyst support, ProKidney remains a pre-profit biotech story, and the stock may be under pressure because investors are still focused on losses and execution risk rather than current earnings strength.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.